Suzhou Asia Pharmaceutical Research and Development Co., Ltd. announced on December 2016 06, its new mechanism of type 2 diabetes innovative drug sodium glucose co transporter (SGLT1) molecule SY-008 clinical research application has completed the Provincial Bureau's verification of the development site and raw data, and formally submitted to the food and Drug Administration of China (SFDA).
This project is the second project of cooperation between Suzhou Yabao and Eli Lilly (phase I clinical has been carried out abroad), and it is also the second project of Yabao to submit clinical research application. Suzhou Yabao pharmaceutical R & D Co., Ltd. (hereinafter referred to as Suzhou Yabao), established less than two years ago, is committed to the development and international cooperation of class 1.1 innovative drugs. At present, the preclinical research data of two innovative drug projects in China have been successfully submitted. This is due to the domestic innovative drug development team established by the founder Dr. Wang Peng, the original R & D data base of Lilly based on sy-008 project, and the joint cooperation with Lilly and experts and units at home and abroad.
About sy-008
Sy-008, sodium glucose co transporter SGLT1 molecule
New targets for diabetes drugs for the Asian population
The diet structure in China is dominated by carbohydrates. SGLT1 inhibitors achieve hypoglycemic effect by inhibiting the absorption of glucose in the intestine, and significantly reduce postprandial blood glucose (more than 80% of postprandial hyperglycemia patients in China). Acarbose, a similar drug, is an oral hypoglycemic drug with sales in China, but the incidence of gastrointestinal adverse reactions is ~ 25%.
About Lilly's Chinese partners
hutchison whampoa
In October 9, 2013, Hutchison Whampoa Pharmaceutical (Shanghai) Limited, Shanghai, was announced to formally sign an agreement with Lilly, and is committed to developing, approving and marketing HMPL-013, a new small molecule anticancer drug, in Chinese mainland.
Cinda biology
On October 12, 2015, Eli Lilly and Cinda biopharmaceutical (Suzhou) Co., Ltd. reached three cooperation agreements on the development of bispecific antibody drugs for tumor immunotherapy, with a total milestone payment of more than US $1 billion.
Suzhou Yabao
In October 20, 2015, the company announced second strategic cooperation with Eli Lilly on diabetes treatment to jointly promote the sodium glucose co transporter (SGLT1) molecule developed by Lilly. Lilly's SGLT1 inhibitor project has completed phase I clinical trials in Singapore and has rich preclinical data. In July 2014, Lilly and Yabao announced the joint development of Lilly's glucokinase activator (GKA), ly2608204.
About Suzhou Yabao
Suzhou Yabao is a biological company committed to developing revolutionary and innovative drugs with international prospects through international cooperation. In April 2014, Dr. Wang Peng, a distinguished expert of the "thousand talents plan", was founded and served as president. He is a holding subsidiary of Yabao Pharmaceutical Group, a well-known domestic listed pharmaceutical company.
In just two and a half years, Suzhou Yabao has established cooperative relations with global famous enterprises and colleges such as Lilly pharmaceutical, University of South Australia, University of Western Ontario, science and Technology Department of British Medical College and so on. And has established a domestic innovative drug development team. At present, eight class 1 innovative drug projects are under research, of which one has completed international clinical phase 1 (Chinese clinical approval has been approved and the approval is in preparation), and the other two are in clinical phase 1.
Innovation, openness and cooperation
Welcome to: www.suzhouyabao.com
请将简历发送至：